FIELD: pharmaceutics.
SUBSTANCE: group of inventions refers to chemical-pharmaceutical industry and represents compound with high penetration ability, which is HCl salt of 1-piperidine ethyl ether 4,4-dioxide [2S-(2alpha, 3beta, 5alpha)]-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl) -4-tia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid (tazobactam-REE), HCl salt of N,N-diethylaminoethyl ether of 4,4-dioxide (2S,5R)-3,3-dimethyl-7-oxo-4-tia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid (sulbactam-DEE), HCl salt of 4-piperidine ethyl ester of (2R,5R,Z)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid (clavulanic acid-REE) , HCl salt (4-nitrophenyl) (N, N-diethylaminomethyl)-ether[(N-benzyloxyicarbonilamino) methyl]-phosphonic acid, HCl salt (3-pyridinyl) (1-piperidinethyl)-ether [(N-benzyloxyicarbonilamino)methyl]-phosphonic acid, HCl salt of 4-(4-dimethylaminobutiril) amidobenzolsulphonamide (DMAB-sulfanilamide), HCl salt of N,N-diethylaminopropil ether 6-oxo-3-(2-[4-(N-pyridine-2-ylsulfamoil)phenyl] hydrazone) cyclogexa-1.4-diencarboxylic acid (sulfasalazine-DEPE), HCl salt of butyl ether 1-cyclopropyl-6-fluoro-4-oxo-7-piperazine-1-yl-quinoline-3-carboxylic acid (ciprofloxacin-VE), HCl salt of N,N-diethylaminoethyl ether 1-ethyl-7-methyl-4-oxo-[1,8] naphtirydine-3-carboxylic acid (nalidixic acid-DEE).
EFFECT: pharmaceutical composition containing effective amount of such compounds and pharmaceutically acceptable carrier.
4 cl, 19 ex, 9 tbl, 6 dwg
